DSM 265

Drug Profile

DSM 265

Alternative Names: DSM-265; PfSPZ

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Monash University; University of Texas Southwestern Medical Center; University of Washington
  • Developer Center for Infectious Disease Research; Fred Hutchinson Cancer Research Center; Medicines for Malaria Venture; Takeda; United States Department of Defense
  • Class Antimalarials; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 19 May 2017 Medicines for Malaria Venture plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000711314)
  • 13 Sep 2016 Medicines for Malaria Venture and AbbVie terminate a phase I bioavailability trial in Healthy volunteers in USA (PO, Granule) (NCT02750384)
  • 01 May 2016 Medicines for Malaria Venture and AbbVie initiate a phase I bioavailability trial in Healthy volunteers in USA (PO, Granule) (NCT02750384)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top